Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
2020_Winter_CMTA_Report
Winter_2020_CMTA_Report
CMTA 2024 Year in Review_ONLINE SPREADS7 (1)
2020_CMTA_PFC_Axonal_Update_transcript
CMTA 2024 Year in Review_6_SPREADS
TAKE ACTION! Sign the Petition to Accelerate CMT-SORD
What is CMT-SORD? In 2019, with Charcot-Marie-Tooth Association (CMTA) funding, researchers discovered CMT-SORD. CMTA Alliance Partner, Applied Therapeutics, then quickly identified a drug which they successfully tested in a newly…
CMTA-Funded Research Database Identifies New Mutations
…evaluate CMT therapies. “The work in Züchner’s lab aligns perfectly with the CMTA’s Strategy to Accelerate Research (STAR),” CMTA CEO Amy Gray said. “Funding this project is another way the…
CMTA Announces Strategic Partnership with Acceleron to Advance CMT Treatment Options
…developing medicines to treat serious and rare diseases, including CMT. The CMTA’s Strategy to Accelerate Research (STAR) connects top CMT clinicians and academic researchers with pharmaceutical partners committed to developing…
Muscular Atrophy and CMT
…neurogenic atrophy sets in with that same muscle, the atrophy becomes nonrecoverable. This is why CMT specialists and the CMTA recommends exercise for CMT patients. While exercise does not treat…
CMTA Alliance Partner, Applied Therapeutics, Announces Positive 12-Month Results in its Ongoing INSPIRE Phase III Trial for CMT-SORD
…statement, Applied Therapeutics said the trial at its 12-month mark has shown a statistically significant correlation between sorbitol levels and the prespecified CMT Functional Outcomes Measure (CMT-FOM) and that treatment…